CN112930393A - 结合诱导的Notch信号传导的过继T细胞疗法的方法和组合物 - Google Patents

结合诱导的Notch信号传导的过继T细胞疗法的方法和组合物 Download PDF

Info

Publication number
CN112930393A
CN112930393A CN201980071074.5A CN201980071074A CN112930393A CN 112930393 A CN112930393 A CN 112930393A CN 201980071074 A CN201980071074 A CN 201980071074A CN 112930393 A CN112930393 A CN 112930393A
Authority
CN
China
Prior art keywords
cells
cys
gly
cell
notch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980071074.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·R·里德尔
I·D·伯恩斯坦
M·J·庞特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of CN112930393A publication Critical patent/CN112930393A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
CN201980071074.5A 2018-08-28 2019-08-28 结合诱导的Notch信号传导的过继T细胞疗法的方法和组合物 Pending CN112930393A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862723936P 2018-08-28 2018-08-28
US62/723,936 2018-08-28
PCT/US2019/048574 WO2020047099A1 (en) 2018-08-28 2019-08-28 Methods and compositions for adoptive t cell therapy incorporating induced notch signaling

Publications (1)

Publication Number Publication Date
CN112930393A true CN112930393A (zh) 2021-06-08

Family

ID=67982131

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980071074.5A Pending CN112930393A (zh) 2018-08-28 2019-08-28 结合诱导的Notch信号传导的过继T细胞疗法的方法和组合物

Country Status (9)

Country Link
US (1) US20210292711A1 (https=)
EP (1) EP3844266A1 (https=)
JP (1) JP2021534785A (https=)
CN (1) CN112930393A (https=)
AU (1) AU2019329984A1 (https=)
BR (1) BR112021003830A2 (https=)
CA (1) CA3110089A1 (https=)
SG (1) SG11202101455TA (https=)
WO (1) WO2020047099A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113832102A (zh) * 2021-09-27 2021-12-24 苏州东岭生物技术有限公司 Cd3/cd28/dll4磁珠及其制备方法和应用
CN116716349A (zh) * 2023-08-01 2023-09-08 江苏集萃药康生物科技股份有限公司 一种dll4人源化小鼠模型的构建方法及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220241335A1 (en) * 2019-07-11 2022-08-04 H. Lee Moffitt Cancer Center And Research Inst5Itute, Inc. Engineering notch ligands to enhance the anti-tumor activity of adoptively transferred t cells
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
WO2022165367A1 (en) * 2021-01-29 2022-08-04 Fred Hutchinson Cancer Research Center Methods and compositions for enhancing cd4+ phenotype for adoptive t cell therapy

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060003927A1 (en) * 2002-10-09 2006-01-05 Champion Brian R Modulation of immune function
EP1616958A2 (en) * 1996-11-07 2006-01-18 Lorantis Limited Notch-ligands for use in immunotherapy
US20080112934A1 (en) * 2004-11-24 2008-05-15 Rafick-Pierre Sekaly Methods To Identify, Prepare, And Use Naive T Cell Recent Thymic Emigrants
US20100136022A1 (en) * 2007-01-30 2010-06-03 Deutsches Rheuma-Forschungszentrum Berlin Method for modulating the immune response by activating or inactivating the notch and/or stat4 signal path
WO2014039044A1 (en) * 2012-09-06 2014-03-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t memory stem cell populations
WO2017070337A1 (en) * 2015-10-20 2017-04-27 Cellular Dynamics International, Inc. Methods for directed differentiation of pluripotent stem cells to immune cells
WO2017075389A1 (en) * 2015-10-30 2017-05-04 The Regents Of The Universtiy Of California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
CN107106611A (zh) * 2014-10-27 2017-08-29 弗雷德哈钦森癌症研究中心 用于提高过继细胞免疫疗法效力的组合物和方法
US20180119100A1 (en) * 2013-02-22 2018-05-03 The Board Of Trustees Of The University Of Illinois T-REG Cell Expansion
CN108431210A (zh) * 2015-10-22 2018-08-21 朱诺治疗学有限公司 培养细胞的方法及用于该方法的试剂盒和设备

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA136551A (en) 1911-08-03 1911-10-31 Hedwig Heeron Rolling mill
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
US20030119771A1 (en) 2001-08-22 2003-06-26 Rompaey Luc Van Modulators of bone homeostasis identified in a high-throughput screen
JP2003093048A (ja) * 2001-09-26 2003-04-02 Asahi Kasei Corp 新規細胞製剤製造用培養媒体
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US20060078552A1 (en) 2002-03-15 2006-04-13 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
JP2006506322A (ja) * 2002-04-05 2006-02-23 ロランティス リミテッド 内科療法
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
JP2006517533A (ja) * 2003-01-23 2006-07-27 ロランティス リミテッド Ｎｏｔｃｈシグナル伝達経路のアクチベーターを用いる自己免疫疾患の治療
US20060153826A1 (en) 2003-01-28 2006-07-13 Sylvain Arnould Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
WO2007027226A2 (en) * 2005-04-28 2007-03-08 Board Of Regents, The University Of Texas System Systems and methods for the production of differentiated cells
CA2891996A1 (en) 2005-10-18 2007-04-26 Duke University Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
EP2081962B1 (en) 2006-10-19 2018-10-03 Genentech, Inc. Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
AR063494A1 (es) 2006-10-19 2009-01-28 Genentech Inc Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
CA2682527C (en) 2007-03-30 2017-07-11 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
WO2010059543A1 (en) 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
WO2010141249A2 (en) 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
JP6208580B2 (ja) 2010-05-17 2017-10-04 サンガモ セラピューティクス， インコーポレイテッド 新規のｄｎａ結合タンパク質及びその使用
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
WO2014093718A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US9683039B2 (en) 2013-03-14 2017-06-20 New York University Notch agonists for the treatment of cancer
EP3760719A1 (en) 2013-11-18 2021-01-06 CRISPR Therapeutics AG Crispr-cas system materials and methods
KR20170007449A (ko) 2014-05-22 2017-01-18 프레드 헛친슨 켄서 리서치 센터 조혈 전구체 세포의 lilrb2 및 노치 매개 증식
BR112016028537A2 (pt) 2014-06-04 2017-08-22 Hutchinson Fred Cancer Res expansão e enxerto de células-tronco utilizando agonistas de notch 1 e/ou de notch 2
JP7049261B2 (ja) * 2016-04-08 2022-04-06 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント 幹細胞および／または前駆細胞からｔ前駆細胞を作製する方法ならびに該ｔ前駆細胞の使用
US11261250B2 (en) 2016-07-22 2022-03-01 Fred Hutchinson Cancer Research Center Bi-specific molecule for cell-specific Notch inhibition and related methods and compositions

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1616958A2 (en) * 1996-11-07 2006-01-18 Lorantis Limited Notch-ligands for use in immunotherapy
US20060003927A1 (en) * 2002-10-09 2006-01-05 Champion Brian R Modulation of immune function
US20080112934A1 (en) * 2004-11-24 2008-05-15 Rafick-Pierre Sekaly Methods To Identify, Prepare, And Use Naive T Cell Recent Thymic Emigrants
US20100136022A1 (en) * 2007-01-30 2010-06-03 Deutsches Rheuma-Forschungszentrum Berlin Method for modulating the immune response by activating or inactivating the notch and/or stat4 signal path
WO2014039044A1 (en) * 2012-09-06 2014-03-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t memory stem cell populations
US20180119100A1 (en) * 2013-02-22 2018-05-03 The Board Of Trustees Of The University Of Illinois T-REG Cell Expansion
CN107106611A (zh) * 2014-10-27 2017-08-29 弗雷德哈钦森癌症研究中心 用于提高过继细胞免疫疗法效力的组合物和方法
WO2017070337A1 (en) * 2015-10-20 2017-04-27 Cellular Dynamics International, Inc. Methods for directed differentiation of pluripotent stem cells to immune cells
CN108431210A (zh) * 2015-10-22 2018-08-21 朱诺治疗学有限公司 培养细胞的方法及用于该方法的试剂盒和设备
WO2017075389A1 (en) * 2015-10-30 2017-05-04 The Regents Of The Universtiy Of California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAREN LAKY等: "Notch Signaling Regulates Antigen Sensitivity of Naive CD4 T Cells by Tuning Co-stimulation+", IMMUNITY, vol. 42, no. 1, pages 80 - 94, XP055654363, DOI: 10.1016/j.immuni.2014.12.027 *
SHIN-ICHI TSUKUMO等: "Notch Governing Mature T Cell Differentiation", J IMMUNOL, vol. 173, no. 12, pages 7109 - 7113, XP055654367, DOI: 10.4049/jimmunol.173.12.7109 *
张悦等: "Notch信号通路调控调节性T细胞分化与功能的研究进展", 现代免疫学, vol. 38, no. 02, pages 162 - 165 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113832102A (zh) * 2021-09-27 2021-12-24 苏州东岭生物技术有限公司 Cd3/cd28/dll4磁珠及其制备方法和应用
CN113832102B (zh) * 2021-09-27 2024-03-12 苏州东岭生物技术有限公司 Cd3/cd28/dll4磁珠及其制备方法和应用
CN116716349A (zh) * 2023-08-01 2023-09-08 江苏集萃药康生物科技股份有限公司 一种dll4人源化小鼠模型的构建方法及其应用
CN116716349B (zh) * 2023-08-01 2023-10-31 江苏集萃药康生物科技股份有限公司 一种dll4人源化小鼠模型的构建方法及其应用

Also Published As

Publication number Publication date
EP3844266A1 (en) 2021-07-07
AU2019329984A1 (en) 2021-03-11
JP2021534785A (ja) 2021-12-16
WO2020047099A1 (en) 2020-03-05
CA3110089A1 (en) 2020-03-05
BR112021003830A2 (pt) 2021-07-20
US20210292711A1 (en) 2021-09-23
SG11202101455TA (en) 2021-03-30

Similar Documents

Publication Publication Date Title
US20250114433A1 (en) Binding proteins specific for ras neoantigens and uses thereof
JP7224318B2 (ja) 養子細胞療法用の操作された細胞
JP7037577B2 (ja) 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用
KR102437015B1 (ko) 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
CN110997902B (zh) Suv39h1缺陷的免疫细胞
KR102617818B1 (ko) 인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제
CN112930393A (zh) 结合诱导的Notch信号传导的过继T细胞疗法的方法和组合物
US20240165232A1 (en) Chimeric receptor proteins and uses thereof
TW202444897A (zh) 嵌合抗原受體(car)、組合物及其使用方法
JP2020535796A (ja) ｓｔｒｅｐタグ特異的キメラ受容体およびその使用
TW202402798A (zh) 對新抗原具特異性之結合蛋白與工程化細胞及其用途
US20220411479A1 (en) Cd20 chimeric antigen receptors and methods of use for immunotherapy
US20220009992A1 (en) T cell receptors specific for mesothelin and their use in immunotherapy
US20250177531A1 (en) Binding proteins specific for ras neoantigens and uses thereof
JP7737978B2 (ja) Ｗｔ－１に特異的なｔ細胞免疫療法
Kramer Delineating the impact of binding-domain affinity and kinetic properties on Chimeric Antigen Receptor T-cell function
WO2022165367A1 (en) Methods and compositions for enhancing cd4+ phenotype for adoptive t cell therapy
WO2024163371A1 (en) Binding proteins specific for mutant p53 and uses thereof
HK40073285A (en) T-cell immunotherapy specific for wt-1
HK40017846A (en) Immune cells defective for suv39h1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210608

WD01 Invention patent application deemed withdrawn after publication